> Mein DÄ

BEKANNTGABEN DER HERAUSGEBER: Bundesärztekammer

Arzneimittelkommission der deutschen Ärzteschaft: Zur Sicherheit von COX-2-Inhibitoren

Dtsch Arztebl 2002; 99(22): A-1535 / B-1308 / C-1223

1.	Simon LS, Weaver AL, Graham DY, Kivitz AJ et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282:1921–1928.
2.	Emery P, Zeidler H, Kvien TK, Guslandi M et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354 :2106–2111.
3.	Laine L, Harper S, SimonT et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-783
4.	Hawkey C, Lain L, Simon T et al.: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2000; 43: 370–377.
5.	Fux R., Mörike K, Gleiter C: Celecoxib. Gegenwärtiger Stellenwert in der Arzneimitteltherapie. Arzneimitteltherapie 2001;19: 307–321.
6.	Silverstein FE, Faich G, Goldstein JL, Simon LS et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA 2000; 284:1247–1255.
7.	Bombardier C., Laine L, Reicin A, Shapiro D et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 232:1520–1528.
8.	FDA CLASS Advisory Committee Briefing Document. February 7, 2001.
9.	Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–959.

Zum Artikel

Login

Passwort vergessen?

Registrieren

Eingeloggt als $LOGINEMAIL$